Skip to main content

Table 1 Effect of title compounds against cell viability of different cell lines

From: Synthesis and in vitro antitumor activity of (1E,4E)-1-aryl-5-(2-((quinazolin-4-yl)oxy)phenyl)-1,4-pentadien-3-one derivatives

Compds

Inhibition rates against different cells (%)a

IC50 (μM)b

MGC-803

PC3

Bcap-37

NIH3T3

MGC-803

PC3

Bcap-37

5a

71.9 ± 0.9

68.5 ± 2.3

44.1 ± 2.6

65.7 ± 1.3

7.69 ± 0.37

9.24 ± 0.46

11.71 ± 0.39

5b

83.5 ± 1.5

78.7 ± 2.4

57.3 ± 2.0

15.4 ± 1.5

5.20 ± 0.51

8.12 ± 0.46

10.05 ± 0.67

5c

79.2 ± 2.8

76.5 ± 1.7

54.2 ± 1.1

16.1 ± 2.7

5.44 ± 0.45

7.85 ± 0.32

9.34 ± 0.52

5d

87.5 ± 0.2

86.3 ± 0.8

58.5 ± 1.3

71.9 ± 1.4

1.72 ± 0.22

2.68 ± 0.43

7.52 ± 0.36

5e

87.0 ± 1.0

75.2 ± 7.8

67.3 ± 3.9

53.8 ± 1.8

1.89 ± 0.26

4.71 ± 0.36

9.6 ± 0.42

5f

90.7 ± 0.6

93.0 ± 1.8

76.5 ± 1.9

21.5 ± 2.7

0.85 ± 0.43

1.37 ± 0.22

4.98 ± 0.39

5g

85.9 ± 1.2

83.1 ± 2.8

74.9 ± 2.0

74.3 ± 0.9

2.02 ± 0.37

2.18 ± 0.31

5.61 ± 0.50

5h

62.3 ± 1.4

43.7 ± 12.1

36.6 ± 2.7

13.4 ± 2.2

9.06 ± 0.40

11.68 ± 0.48

15.64 ± 0.51

5i

79.4 ± 2.4

65.1 ± 2.6

47.1 ± 2.6

14.4 ± 2.6

7.78 ± 0.48

9.36 ± 0.52

10.73 ± 0.62

5j

76.3 ± 0.8

71.9 ± 3.1

45.4 ± 2.2

41.0 ± 2.1

6.42 ± 0.44

8.64 ± 0.47

12.11 ± 0.31

5k

82.1 ± 3.0

76.3 ± 2.5

60.2 ± 1.4

3.0 ± 2.3

2.94 ± 0.32

8.12 ± 0.46

8.92 ± 0.58

5l

61.2 ± 1.3

55.7 ± 1.5

54.6 ± 1.0

0.8 ± 1.6

4.33 ± 0.35

9.08 ± 0.52

9.83 ± 0.46

5m

81.1 ± 1.7

81.2 ± 2.8

66.4 ± 1.5

12.4 ± 2.5

2.05 ± 0.39

3.79 ± 0.47

7.82 ± 0.39

5n

78.7 ± 2.7

69.0 ± 1.7

55.8 ± 1.1

29.6 ± 2.4

3.33 ± 0.42

4.16 ± 0.43

8.70 ± 0.54

ADMc

97.5 ± 1.2

91.2 ± 0.4

94.5 ± 0.9

100.0 ± 0.7

0.74 ± 0.24

1.01 ± 0.20

1.90 ± 0.25

  1. aInhibitory percentages of cells treated with 10 μM concentration of each compound for 72 h
  2. bAgent concentration (μM) that inhibited cell growth by 50% at 72 h after treatment
  3. cAdriamycin, positive control